Ironwood Pharmaceuticals, Inc.
IRWD
$3.58
-$0.09-2.45%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 158.87% | -47.31% | 33.26% | -9.70% | -45.05% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 158.87% | -47.31% | 33.26% | -9.70% | -45.05% |
| Cost of Revenue | -20.02% | -13.89% | -24.67% | -23.08% | 6.26% |
| Gross Profit | 516.77% | -60.33% | 61.24% | -3.35% | -72.05% |
| SG&A Expenses | -50.40% | -42.03% | -39.33% | -54.56% | -35.49% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -34.28% | -29.79% | -32.70% | -40.36% | -18.49% |
| Operating Income | 787.58% | -79.05% | 202.84% | 66.66% | -192.07% |
| Income Before Tax | 279.68% | -98.10% | 291.62% | 100.37% | -831.59% |
| Income Tax Expenses | 2,090.22% | -87.44% | 103.60% | -27.93% | -87.79% |
| Earnings from Continuing Operations | 209.06% | -200.89% | 999.29% | 2,844.07% | -798.27% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 209.06% | -200.89% | 999.29% | 2,844.07% | -798.27% |
| EBIT | 787.58% | -79.05% | 202.84% | 66.66% | -192.07% |
| EBITDA | 824.69% | -77.96% | 198.78% | 65.29% | -184.13% |
| EPS Basic | 207.45% | -199.29% | 983.77% | 2,801.85% | -779.55% |
| Normalized Basic EPS | 462.06% | -99.15% | 297.94% | 76.43% | -421.50% |
| EPS Diluted | 203.36% | -270.92% | 1,047.00% | 1,474.00% | -674.00% |
| Normalized Diluted EPS | 454.94% | -99.15% | 264.16% | 61.36% | -421.50% |
| Average Basic Shares Outstanding | 1.54% | 1.59% | 1.57% | 1.70% | 2.08% |
| Average Diluted Shares Outstanding | 3.55% | 1.26% | 10.94% | 11.21% | 2.08% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |